RNA inference-mediated caveolin-1 down-regulation decrease estrogen receptor alpha (ERα) signaling in human mammary epithelial cells.
Several evidences support that caveolin-1 is associated with mammary cell transformation and oncogenesis. We have previously reported that a cell line, named MCF10A-ST1 (ST1), which only expressed 30% Cav-1 compared with parental cells MCF10A (human mammary epithelial cell line) was isolated by gene trapping. The decreased expression of Cav-1 is sufficient for phenotypic transformation of MCF10A cells, which involved in the loss of anchorage-dependent growth and migration in nude mice with the existence of E2. The previous study in our lab on microarray assay showed that the expression of cyclin D1 (cell cycle protein) was up-regulated in ST1 cell line. Here, we not only confirmed the results by Western Blot but also demonstrated that Cav-1 down-regulation accelerate the progression of mammary cells from G1 phase into S phase by Flow Cytometry (FCM). This proposed that the Cav-1 down-regulation could change the progress of cell cycle in the mammary cells. Otherwise, microarray assay also showed that the transcription factor (c-Jun) was up-regulated. But, the original carcinoma gene (c-Fos) and transcription factor (AP-1) have not obviously changed compared with MCF10A. ST1 cells obtained the morigenicity in nude mice with the existence of E2, and the immunoprecipitation showed the interactions of Cav-1 with ERα in both MCF10A and ST1. ERα expression was increased as further down-regulation of Cav-1. So, we hypothesize that Cav-1 down-regulation could induce the activation of ERα-associated signaling pathway, in order to adjust the development and proliferation. By siRNA technology, the down regulation of Cav-1 could activate MAP kinase and Akt signaling pathway, including the phosphorylation of ERK1/2 and Akt. However, the mechanism of Cav-1 down-regulation in the early transformation and signaling transduction of mammary epithelial cells is unclear. Here, we report that down-regulation of caveolin-1 protein expression leads to deregulate estrogen receptor alpha (ERα) signaling and consequently early transformation in mammary epithelia.
Wang
Xi
X
College of Life Science, Liaoning Normal University, 116029, Dalian, China.
Feng
Shuang
S
Zhang
Hong
H
Wang
Yang
Y
Cui
Yuying
Y
Wang
Zhaoyi
Z
Liu
Jing
J
Zou
Wei
W
D000818:Animals; D051242:Caveolin 1 / Q000096:biosynthesis*; D002460:Cell Line; D045744:Cell Line, Tumor; D002465:Cell Movement; D015536:Down-Regulation; D004847:Epithelial Cells / Q000166:cytology*; D047628:Estrogen Receptor alpha / Q000235:genetics*; D006801:Humans; D042361:Mammary Glands, Human / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D010641:Phenotype; D034622:RNA Interference; D015398:Signal Transduction
D051242:Caveolin 1; D047628:Estrogen Receptor alpha
Exp Cell Res. 1999 Nov 25;253(1):255-70
10579927
J Biol Chem. 1998 Aug 7;273(32):20448-55
9685399
Mol Biol Rep. 2008 Mar;35(1):23-7
17415682
Mol Pharmacol. 2009 Aug;76(2):425-39
19487245
J Biol Chem. 1996 Nov 15;271(46):29182-90
8910575
J Endocrinol. 2008 Feb;196(2):385-97
18252962
Proc Natl Acad Sci U S A. 2000 May 23;97(11):5930-5
10823945
Anticancer Res. 2003 Nov-Dec;23(6C):4581-6
14981899
J Cell Physiol. 2001 Mar;186(3):329-37
11169971
BMC Res Notes. 2009 Jul 17;2:140
19615042
FEBS Lett. 1998 Jun 16;429(3):330-6
9662443
Science. 1995 Mar 31;267(5206):2003-6
7701324
Mol Cell Biol. 2000 Jan;20(2):672-83
10611246
J Cell Mol Med. 2008 Jun;12(3):796-809
18315571
J Biol Chem. 1995 Jul 14;270(28):16483-6
7622446
Mol Biol Rep. 2004 Jun;31(2):67-84
15293782
Circulation. 2000 Feb 15;101(6):660-7
10673259
J Cell Physiol. 2001 Aug;188(2):170-7
11424083
Am J Pathol. 2006 Jun;168(6):1998-2013
16723714
Am J Physiol Cell Physiol. 2005 Mar;288(3):C494-506
15692148
Cancer Res. 1996 Mar 1;56(5):1098-1103
8640767
Breast Cancer Res. 2005;7(1):R130-44
15642162
J Cell Biochem. 2005 Oct 15;96(3):490-505
16092128
Breast Cancer Res Treat. 2003 Feb;77(3):265-75
12602926
Endocrinology. 1997 Sep;138(9):4030-3
9275096
Endocr Rev. 2007 Dec;28(7):726-41
17916740
Mol Endocrinol. 2002 Jan;16(1):100-15
11773442
FASEB J. 2002 Jan;16(1):114-6
11709495
Cell. 2001 Jan 12;104(1):21-32
11163237
Pharmacol Rev. 2002 Sep;54(3):431-67
12223531
Int J Cancer. 2000 Aug 15;87(4):468-72
10918184
Mol Endocrinol. 2000 Sep;14(9):1434-47
10976921
Mol Biol Cell. 2005 Jan;16(1):231-7
15496458